A synthetic FXR agonist, GW4064, inhibits the leptin-induced tumor-promoting activities of CAFs and CAF-conditioned medium in BC cells by inhibiting growth, motility, and invasiveness in vitro [542]. Here, LEP is linked to breast cancer.